[Skip to Content]
[Skip to Content Landing]
Views 278
Citations 0
Comment & Response
January 16, 2020

Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer—Reply

Author Affiliations
  • 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University, Portland
  • 2Health Services Research and Development, Veterans Affairs Portland Health Care System, Portland, Oregon
  • 3Section of Pulmonary and Critical Care Medicine, Veterans Affairs Portland Health Care System, Portland, Oregon
JAMA Oncol. 2020;6(3):443-444. doi:10.1001/jamaoncol.2019.6301

In Reply We thank Skelin and colleagues for their comments regarding our study1 evaluating the association of early palliative care with survival among patients with advanced lung cancer. Performance status is an important parameter in cancer treatment decision-making, and the Eastern Cooperative Oncology Group scale is one set of criteria used to encourage standardized reporting of treatment toxic effects and response, especially in the conduct of randomized clinical trials. Unfortunately, interrater reliability is inconsistent,2 inherent clinician bias may contribute to inconsistencies,3 and missing values are common in administrative data. Instead, we included the Charlson Comorbidity Index score, which measures comorbidities, and the Functional Comorbidity Index score, which measures physical function to predict survival in modeling, as surrogates of performance status because both are well validated in administrative data. Ultimately, treatment decision-making in oncology is complex, multifactorial, and influenced by clinician-related and patient-related factors; therefore, no single measure of patient suitability for treatment is likely to be sufficient.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×